Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 45

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Histopathologic Manifestations of Drug-induced Hepatotoxicity

Zhang, Xuchen, Ouyang, Jie, Thung, Swan N.·2013·Clinics in Liver Disease
DOI 10.1016/j.cld.2013.07.004
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cld.2013.07.004

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 114

  1. Bleibel, 2007, Drug-induced liver injury: review article, Dig Dis Sci, 52, 2463, 10.1007/s10620-006-9472-y · DOI
  2. Tujios, 2011, Mechanisms of drug-induced liver injury: from bedside to bench, Nat Rev Gastroenterol Hepatol, 8, 202, 10.1038/nrgastro.2011.22 · DOI · Paper page
  3. Davern, 2012, Drug-induced liver disease, Clin Liver Dis, 16, 231, 10.1016/j.cld.2012.03.002 · DOI
  4. Kleiner, 2009, The pathology of drug-induced liver injury, Semin Liver Dis, 29, 364, 10.1055/s-0029-1240005 · DOI
  5. Andrade, 2007, Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists, World J Gastroenterol, 13, 329, 10.3748/wjg.v13.i3.329 · DOI
  6. Gan, 1982, Dapsone-induced infectious mononucleosis-like syndrome, Med J Aust, 1, 350, 10.5694/j.1326-5377.1982.tb132347.x · DOI
  7. Spigset, 1998, Drug-induced hepatic injuries, Tidsskr Nor Laegeforen, 118, 2805
  8. Dalton, 2007, The role of hepatitis E virus testing in drug-induced liver injury, Aliment Pharmacol Ther, 26, 1429, 10.1111/j.1365-2036.2007.03504.x · DOI
  9. Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury, Gastroenterology, 141, 1665, 10.1053/j.gastro.2011.07.051 · DOI · Paper page
  10. Lee, 1995, Drug-induced hepatotoxicity, N Engl J Med, 333, 1118, 10.1056/NEJM199510263331706 · DOI · Paper page
  11. Bjornsson, 2007, Long-term follow-up of patients with mild to moderate drug-induced liver injury, Aliment Pharmacol Ther, 26, 79, 10.1111/j.1365-2036.2007.03355.x · DOI
  12. Andrade, 2006, Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry, Hepatology, 44, 1581, 10.1002/hep.21424 · DOI · Paper page
  13. Hou, 2012, Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes, Cell Biochem Biophys, 64, 77, 10.1007/s12013-012-9373-y · DOI
  14. Bunchorntavakul, 2013, Herbal and dietary supplement hepatotoxicity, Aliment Pharmacol Ther, 37, 3, 10.1111/apt.12109 · DOI · Paper page
  15. Efe, 2013, Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship?, Autoimmun Rev, 12, 337, 10.1016/j.autrev.2012.03.010 · DOI
  16. Czaja, 2011, Drug-induced autoimmune-like hepatitis, Dig Dis Sci, 56, 958, 10.1007/s10620-011-1611-4 · DOI · Paper page
  17. Suzuki, 2011, The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury, Hepatology, 54, 931, 10.1002/hep.24481 · DOI · Paper page
  18. Lewis, 2011, Diagnosis: liver biopsy differentiates DILI from autoimmune hepatitis, Nat Rev Gastroenterol Hepatol, 8, 540, 10.1038/nrgastro.2011.140 · DOI
  19. Ramachandran, 2009, Histological patterns in drug-induced liver disease, J Clin Pathol, 62, 481, 10.1136/jcp.2008.058248 · DOI · Paper page
  20. Yoshikado, 2013, Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites, Mol Pharmacol, 83, 552, 10.1124/mol.112.081752 · DOI
  21. Vilas-Boas, 2012, Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature, Gastroenterol Hepatol, 35, 560, 10.1016/j.gastrohep.2012.05.007 · DOI
  22. Studniarz, 2012, Amoxicillin/clavulanic acid-induced cholestatic liver injury after pediatric liver transplantation, Ann Transplant, 17, 128, 10.12659/AOT.882646 · DOI
  23. Ruiz Rebollo, 2011, Amoxicillin-induced cholestatic hepatitis, Gastroenterol Hepatol, 34, 474, 10.1016/j.gastrohep.2011.05.001 · DOI
  24. Stadlmann, 2012, Venlafaxine-induced cholestatic hepatitis: case report and review of literature, Am J Surg Pathol, 36, 1724, 10.1097/PAS.0b013e31826af296 · DOI
  25. Nojkov, 2012, Lenalidomide-associated hepatotoxicity—a case report and literature review, Anticancer Res, 32, 4117
  26. Devarbhavi, 2011, Antituberculous drug-induced liver injury: current perspective, Trop Gastroenterol, 32, 167
  27. Avelar-Escobar, 2012, Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes, Ann Hepatol, 11, 564, 10.1016/S1665-2681(19)31474-7 · DOI · Paper page
  28. Palta, 2009, Prolonged cholestasis associated with benazepril therapy, Am J Gastroenterol, 104, 245, 10.1038/ajg.2008.42 · DOI
  29. Yeung, 2003, Ramipril-associated hepatotoxicity, Arch Pathol Lab Med, 127, 1493, 10.5858/2003-127-1493-RH · DOI
  30. Alazmi, 2006, Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy, J Clin Gastroenterol, 40, 353, 10.1097/01.mcg.0000210098.28876.66 · DOI
  31. Qu, 2011, Sclerosing cholangitis after transcatheter arterial chemoembolization: a case report, Chin Med Sci J, 26, 190, 10.1016/S1001-9294(11)60047-3 · DOI
  32. Siddique, 2012, Approach to a patient with elevated serum alkaline phosphatase, Clin Liver Dis, 16, 199, 10.1016/j.cld.2012.03.012 · DOI
  33. Plessier, 2012, Management of hepatic vascular diseases, J Hepatol, 56, S25, 10.1016/S0168-8278(12)60004-X · DOI
  34. Elbl, 2012, Herbal drugs mimicking primary biliary cirrhosis, Praxis (Bern 1994), 101, 195, 10.1024/1661-8157/a000829 · DOI
  35. Nakayama, 2011, Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin, Indian J Gastroenterol, 30, 97, 10.1007/s12664-011-0092-x · DOI
  36. Macias, 2003, Ductopenic hepatitis related to Enalapril, J Hepatol, 39, 1091, 10.1016/j.jhep.2003.08.029 · DOI
  37. Nakanuma, 2001, Pathology and pathogenesis of intrahepatic bile duct loss, J Hepatobiliary Pancreat Surg, 8, 303, 10.1007/s005340170002 · DOI
  38. Vuppalanchi, 2006, Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide, Am J Surg Pathol, 30, 1619, 10.1097/01.pas.0000213342.78475.48 · DOI
  39. Kleiner, 2012, Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research, Semin Liver Dis, 32, 3, 10.1055/s-0032-1306421 · DOI · Paper page
  40. Khan, 2009, Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases, J Hepatobiliary Pancreat Surg, 16, 137, 10.1007/s00534-008-0016-z · DOI
  41. Tannapfel, 2011, Steatohepatitis after chemotherapy for colorectal liver metastases (CASH), Pathologe, 32, 330, 10.1007/s00292-011-1434-2 · DOI
  42. Coash, 2012, Granulomatous liver diseases: a review, J Formos Med Assoc, 111, 3, 10.1016/j.jfma.2011.11.023 · DOI
  43. Turhan, 2011, Hepatic granulomas: a clinicopathologic analysis of 86 cases, Pathol Res Pract, 207, 359, 10.1016/j.prp.2011.03.003 · DOI
  44. Gaya, 2003, Hepatic granulomas: a 10 year single centre experience, J Clin Pathol, 56, 850, 10.1136/jcp.56.11.850 · DOI
  45. Fiel, 2008, Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation, Transpl Infect Dis, 10, 184, 10.1111/j.1399-3062.2007.00258.x · DOI
  46. Farah, 2008, Granulomatous hepatitis associated with etanercept therapy, J Rheumatol, 35, 349
  47. Braun, 1999, Mesalamine-induced granulomatous hepatitis, Am J Gastroenterol, 94, 1973, 10.1111/j.1572-0241.1999.01245.x · DOI
  48. Ruiz-Valverde, 1995, Ticlopidine-induced granulomatous hepatitis, Ann Pharmacother, 29, 633, 10.1177/106002809502900618 · DOI
  49. Vial, 1993, Drug-induced granulomatous hepatitis, Gastroenterol Clin Biol, 17, H44
  50. Flamm, 2012, Granulomatous liver disease, Clin Liver Dis, 16, 387, 10.1016/j.cld.2012.03.013 · DOI
  51. Trivalle, 1991, Liver lipogranulomas with log-term fever caused by paraffin oil, Gastroenterol Clin Biol, 15, 551
  52. Dincsoy, 1982, Lipogranulomas in non-fatty human livers. A mineral oil induced environmental disease, Am J Clin Pathol, 78, 35, 10.1093/ajcp/78.1.35 · DOI
  53. Fleming, 1998, Granulomas in the livers of humans and Fischer rats associated with the ingestion of mineral hydrocarbons: a comparison, Regul Toxicol Pharmacol, 27, 75, 10.1006/rtph.1997.1109 · DOI
  54. Zhu, 2010, Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease, World J Gastroenterol, 16, 5065, 10.3748/wjg.v16.i40.5065 · DOI
  55. Villamil-Cajoto, 2010, Granulomatous hepatitis due to Mycobacterium complex following Bacillus Calmette-Guérin intravesical instillation, Enferm Infecc Microbiol Clin, 28, 759, 10.1016/j.eimc.2010.06.003 · DOI
  56. Stricker, 1989, Fibrin ring granulomas and allopurinol, Gastroenterology, 96, 1199, 10.1016/0016-5085(89)91641-7 · DOI
  57. Khanlari, 2008, Hepatitis with fibrin-ring granulomas, Infection, 36, 381, 10.1007/s15010-007-6365-8 · DOI
  58. Tjwa, 2001, Hepatic fibrin-ring granulomas in granulomatous hepatitis: report of four cases and review of the literature, Acta Clin Belg, 56, 341, 10.1179/acb.2001.051 · DOI
  59. Rubbia-Brandt, 2010, Sinusoidal obstruction syndrome, Clin Liver Dis, 14, 651, 10.1016/j.cld.2010.07.009 · DOI
  60. Sebagh, 2011, Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation, Liver Transpl, 17, 798, 10.1002/lt.22282 · DOI
  61. Robinson, 2012, Hepatic sinusoidal obstruction syndrome reduces the effect of oxaliplatin in colorectal liver metastases, Histopathology, 61, 1247, 10.1111/j.1365-2559.2012.04358.x · DOI
  62. Tuncer, 2012, Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation, World J Gastroenterol, 18, 1851, 10.3748/wjg.v18.i16.1851 · DOI
  63. Pai, 2012, Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant, Leuk Lymphoma, 53, 1552, 10.3109/10428194.2012.661052 · DOI
  64. Gao, 2012, Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids, J Dig Dis, 13, 33
  65. Larrey, 2011, Herbal medicine hepatotoxicity: a new step with development of specific biomarkers, J Hepatol, 54, 599, 10.1016/j.jhep.2010.12.003 · DOI
  66. Corbacioglu, 2012, Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation, Expert Rev Hematol, 5, 291, 10.1586/ehm.12.18 · DOI
  67. Platzbecker, 2012, SOS for veno-occlusive disease: defibrotide prophylaxis, Lancet, 379, 1277, 10.1016/S0140-6736(12)60067-1 · DOI
  68. Richardson, 2013, Drug safety evaluation of defibrotide, Expert Opin Drug Saf, 12, 123, 10.1517/14740338.2012.749855 · DOI
  69. van Erpecum, 1988, Generalized peliosis hepatis and cirrhosis after long-term use of oral contraceptives, Am J Gastroenterol, 83, 572
  70. Neri, 2011, Anabolic androgenic steroids abuse and liver toxicity, Mini Rev Med Chem, 11, 430, 10.2174/138955711795445916 · DOI
  71. Komori, 2010, Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients, Int J Clin Oncol, 15, 263, 10.1007/s10147-010-0046-9 · DOI
  72. Gisbert, 2007, Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review, Am J Gastroenterol, 102, 1518, 10.1111/j.1572-0241.2007.01187.x · DOI
  73. Nam, 2012, Chemotherapy-associated hepatopathy in Korean colorectal cancer liver metastasis patients: oxaliplatin-based chemotherapy and sinusoidal injury, Korean J Pathol, 46, 22, 10.4132/KoreanJPathol.2012.46.1.22 · DOI
  74. Ryan, 2010, Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy, Am J Surg Pathol, 34, 784, 10.1097/PAS.0b013e3181dc242c · DOI
  75. Agostini, 2012, Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation, J Hepatol, 56, 869, 10.1016/j.jhep.2011.10.023 · DOI
  76. Cazals-Hatem, 2011, Obliterative portal venopathy: portal hypertension is not always present at diagnosis, J Hepatol, 54, 455, 10.1016/j.jhep.2010.07.038 · DOI
  77. Schouten, 2011, Idiopathic noncirrhotic portal hypertension, Hepatology, 54, 1071, 10.1002/hep.24422 · DOI · Paper page
  78. Krishnan, 2012, Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation, AJR Am J Roentgenol, 198, 370, 10.2214/AJR.11.6855 · DOI
  79. Mendizabal, 2009, Noncirrhotic portal hypertension: another cause of liver disease in HIV patients, Ann Hepatol, 8, 390, 10.1016/S1665-2681(19)31757-0 · DOI
  80. Schiano, 2007, Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV, Am J Gastroenterol, 102, 2536, 10.1111/j.1572-0241.2007.01428.x · DOI
  81. Lawal, 2012, Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt, Clin Colorectal Cancer, 11, 224, 10.1016/j.clcc.2012.02.002 · DOI
  82. Lopez-Martin, 2011, Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease, Gastroenterol Hepatol, 34, 16
  83. Calabrese, 2011, Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease, J Crohns Colitis, 5, 48, 10.1016/j.crohns.2010.08.007 · DOI
  84. Vispo, 2010, Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings, AIDS, 24, 1171, 10.1097/QAD.0b013e3283389e26 · DOI
  85. Schiano, 2011, The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV, Virchows Arch, 458, 231, 10.1007/s00428-010-1004-7 · DOI
  86. Jones, 2012, Liver toxicity of antiretroviral drugs, Semin Liver Dis, 32, 167, 10.1055/s-0032-1316472 · DOI
  87. Jackson, 2012, Non-cirrhotic portal hypertension in HIV mono-infected patients, J Gastroenterol Hepatol, 27, 1512, 10.1111/j.1440-1746.2012.07148.x · DOI
  88. Lefkowitch, 2006, Ground-glass, polyglucosan-like hepatocellular inclusions: a “new” diagnostic entity, Gastroenterology, 131, 713, 10.1053/j.gastro.2006.07.006 · DOI
  89. Bua, 2010, Hepatic glycogenosis in an adolescent with diabetes, J Pediatr, 157, 1042, 10.1016/j.jpeds.2010.06.018 · DOI
  90. Torbenson, 2006, Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus, Am J Surg Pathol, 30, 508, 10.1097/00000478-200604000-00012 · DOI
  91. Carcione, 2003, Liver glycogenosis as early manifestation in type 1 diabetes mellitus, Diabetes Nutr Metab, 16, 182
  92. Abaci, 2008, Hepatic glycogenosis: a rare cause of hepatomegaly in Type 1 diabetes mellitus, J Diabetes Complications, 22, 325, 10.1016/j.jdiacomp.2007.11.002 · DOI
  93. Cuthbertson, 2007, Hepatic glycogenosis: abnormal liver function tests in Type 1 diabetes, Diabet Med, 24, 322, 10.1111/j.1464-5491.2007.02085.x · DOI
  94. Iancu, 1986, Hepatomegaly following short-term high-dose steroid therapy, J Pediatr Gastroenterol Nutr, 5, 41, 10.1097/00005176-198601000-00008 · DOI
  95. Reasor, 2006, Drug-induced phospholipidosis: issues and future directions, Expert Opin Drug Saf, 5, 567, 10.1517/14740338.5.4.567 · DOI
  96. Guigui, 1988, Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease, Hepatology, 8, 1063, 10.1002/hep.1840080514 · DOI
  97. Degott, 1988, Liver phospholipidosis induced by parenteral nutrition: histologic, histochemical, and ultrastructural investigations, Gastroenterology, 95, 183, 10.1016/0016-5085(88)90309-5 · DOI
  98. Obert, 2007, An immunohistochemical approach to differentiate hepatic lipidosis from hepatic phospholipidosis in rats, Toxicol Pathol, 35, 728, 10.1080/01926230701481956 · DOI
  99. Levine, 2003, Stellate-cell lipidosis in liver biopsy specimens. Recognition and significance, Am J Clin Pathol, 119, 254, 10.1309/6DKC03C4GAAEN2DK · DOI
  100. Nollevaux, 2006, Hypervitaminosis A-induced liver fibrosis: stellate cell activation and daily dose consumption, Liver Int, 26, 182, 10.1111/j.1478-3231.2005.01207.x · DOI
  101. Masia, 2012, A histopathologic pattern of centrilobular hepatocyte injury suggests 6-mercaptopurine-induced hepatotoxicity in patients with inflammatory bowel disease, Arch Pathol Lab Med, 136, 618, 10.5858/arpa.2011-0214-OA · DOI
  102. Chang, 2013, Changing epidemiology of hepatocellular adenoma in the United States: review of the literature, Int J Hepatol, 2013, 604860, 10.1155/2013/604860 · DOI
  103. Deneve, 2009, Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy, Ann Surg Oncol, 16, 640, 10.1245/s10434-008-0275-6 · DOI
  104. Socas, 2005, Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature, Br J Sports Med, 39, e27, 10.1136/bjsm.2004.013599 · DOI
  105. Martin, 2008, Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage, World J Gastroenterol, 14, 4573, 10.3748/wjg.14.4573 · DOI
  106. Bork, 2002, Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema, J Hepatol, 36, 707, 10.1016/S0168-8278(02)00035-1 · DOI
  107. Lautz, 2008, Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy, J Pediatr Surg, 43, 751, 10.1016/j.jpedsurg.2007.11.036 · DOI
  108. Tazawa, 1999, Multiple hepatocellular adenomas associated with long-term carbamazepine, Histopathology, 35, 92, 10.1046/j.1365-2559.1999.0728g.x · DOI
  109. Cerminara, 2012, Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report, Childs Nerv Syst, 28, 939, 10.1007/s00381-011-1636-1 · DOI
  110. Defrance, 1982, Association of hepatocellular adenoma and focal nodular hyperplasia of the liver in a woman on oral contraceptives, Gastroenterol Clin Biol, 6, 949
  111. Hagay, 1988, Oral contraceptives and focal nodular hyperplasia of the liver, Arch Gynecol Obstet, 243, 231, 10.1007/BF00932273 · DOI
  112. Tajada, 2001, Liver adenoma and focal nodular hyperplasia associated with oral contraceptives, Eur J Contracept Reprod Health Care, 6, 227, 10.1080/ejc.6.4.227.230 · DOI
  113. Ikeda, 2011, Pelioid-type well-differentiated hepatocellular carcinoma in a patient with a history of taking oral contraceptives: report of a case, Surg Today, 41, 1270, 10.1007/s00595-010-4465-z · DOI
  114. Singhal, 2009, Multifocal epitheloid hemangioendothelioma of liver after long-term oral contraceptive use—a case report and discussion of management difficulties encountered, J Gastrointest Cancer, 40, 59, 10.1007/s12029-009-9083-x · DOI

Cited by

Metadata

Authors
Zhang, X., Ouyang, J., & Thung, S. N.
Venue
Clinics in Liver Disease
Publisher
Elsevier BV
Published
2013-11
Volume
17
Issue
4
Pages
547-564
ISSN
1089-3261
DOI
10.1016/j.cld.2013.07.004
Cited by
45
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.